Cardiogenesis ploughs on with US efforts for heart laser device
This article was originally published in Clinica
Following a catalogue of setbacks in its attempt to gain US market approval for its percutaneous heart laser device for treating angina, Cardiogenesis has submitted to the FDA a trial protocol to initiate yet another study of the controversial treatment.
You may also be interested in...
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.